Previous studies of selumetinib in patients with PNs reported minor AEs (nausea, vomiting, diarrhea, asymptomatic CPK elevation, acneiform rash, and paronychia) and an acceptable safety profile in long-term use among pediatric populations [5, 24, 25, 34, 35]. Here, PIK3C2A is linked to paronychia.